Sickle Cell Disease — Deal Benchmarks & Valuation
Market Analysis
Sickle Cell Disease is one of the most actively transacted indications in rare disease licensing. Phase 1 deals for sickle cell disease carry a median total deal value of $1.1B, with upfront payments ranging from $46M to $200M. The recommended deal structure allocates approximately 11% to upfront payments and 89% to milestones.
Milestone structures for sickle cell disease deals allocate $347M to development milestones, $268M to regulatory milestones, and $377M to commercial milestones. Royalty rates range from 6.1% to 12.1% at the base tier, with tiered escalation reaching 10.1%-16.1% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for sickle cell disease licensing?
What royalty rates are standard for sickle cell disease deals?
How are sickle cell disease deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.